Higher cross-subtype IFN-γ ELISpot responses to Gag and Nef peptides in Brazilian HIV-1 subtype B- and F1- than in C-infected subjects

Vaccine

Volumn 31, Issue 7, 2013, Pages 1106-1112

  Côrtes, Fernanda Heloise ^a   Bello, Gonzalo ^a   Vorsatz, Carla ^b   Pilotto, José Henrique ^a,c   Guimarães, Monick Lindenmeyer ^a   Grinsztejn, Beatriz ^b   Veloso, Valdiléa Gonçalves ^b   Pinto, Aguinaldo Roberto ^d   Morgado, Mariza Gonçalves ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Funda??o Oswaldo Cruz   (Brazil)

^c Hospital Geral de Nova Iguacu   (Brazil)

^d FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Consensus versus isolate sequences; Cross reactivity; Gag; HIV 1 subtypes; Nef; T cell response

Indexed keywords

CLOSEST VIRAL ISOLATE; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; NEF PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONSENSUS; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSPOT ASSAY; GENE SEQUENCE; GENETIC DISTANCE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; PRIORITY JOURNAL; VIRUS IMMUNITY; VIRUS STRAIN; VIRUS TYPING;

BRAZIL; CROSS REACTIONS; ENZYME-LINKED IMMUNOSPOT ASSAY; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-GAMMA; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES;

EID: 84872620454     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.12.023     Document Type: Article

References (48)

1. Girard M.P., Osmanov S., Assossou O.M., Kieny M.P. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review. Vaccine 2011, 29(37):6191-6218.
2. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361(23):2209-2220.
3. Boutwell C.L., Rolland M.M., Herbeck J.T., Mullins J.I., Allen T.M. Viral evolution and escape during acute HIV-1 infection. J Infect Dis 2010, 202(October (Suppl 2)):S309-S314.
4. Garber D.A., Silvestri G., Feinberg M.B. Prospects for an AIDS vaccine: three big questions, no easy answers. Lancet Infect Dis 2004, 4(7):397-413.
5. Korber B., Gaschen B., Yusim K., Thakallapally R., Kesmir C., Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 2001, 58:19-42.
6. Morgado M.G., Guimaraes M.L., Gripp C.B., Costa C.I., Neves I., Veloso V.G., et al. Molecular epidemiology of HIV-1 in Brazil: high prevalence of HIV-1 subtype B and identification of an HIV-1 subtype D infection in the city of Rio de Janeiro, Brazil. Evandro Chagas Hospital AIDS Clinical Research Group. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 18(August (5)):488-494.
7. Caride E., Brindeiro R., Hertogs K., Larder B., Dehertogh P., Machado E., et al. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART. Virology 2000, 275(September (1)):107-115.
8. Machado L.F., Ishak M.O., Vallinoto A.C., Lemos J.A., Azevedo V.N., Moreira M.R., et al. Molecular epidemiology of HIV type 1 in northern Brazil: identification of subtypes C and D and the introduction of CRF02_AG in the Amazon region of Brazil. AIDS Res Hum Retroviruses 2009, 25(October (10)):961-966.
9. Ferreira A.S., Cardoso L.P., Stefani M.M. Moderate prevalence of transmitted drug resistance and high HIV-1 genetic diversity in patients from Mato Grosso State, Central Western Brazil. J Med Virol 2011, 83(August (8)):1301-1307.
10. Gräf T., Passaes C.P., Ferreira L.G., Grisard E.C., Morgado M.G., Bello G., et al. HIV-1 genetic diversity and drug resistance among treatment naïve patients from Southern Brazil: an association of HIV-1 subtypes with exposure categories. J Clin Virol 2011, 51(July (3)):186-191.
11. Montano S.M., Sanchez J.L., Laguna-Torres A., Cuchi P., Avila M.M., Weissenbacher M., et al. Prevalences, genotypes, and risk factors for HIV transmission in South America. J Acquir Immune Defic Syndr 2005, 40(September (1)):57-64.
12. Gomez-Carrillo M., Pampuro S., Duran A., Losso M., Harris D.R., Read J.S., et al. Analysis of HIV type 1 diversity in pregnant women from four Latin American and Caribbean countries. AIDS Res Hum Retroviruses 2006, 22(11):1186-1191.
13. Aguayo N., Laguna-Torres V.A., Villafane M., Barboza A., Sosa L., Chauca G., et al. Epidemiological and molecular characteristics of HIV-1 infection among female commercial sex workers, men who have sex with men and people living with AIDS in Paraguay. Rev Soc Bras Med Trop 2008, 41(May-June (3)):225-231.
14. Fischer W., Perkins S., Theiler J., Bhattacharya T., Yusim K., Funkhouser R., et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med 2007, 13(1):100-106.
15. Gaschen B., Taylor J., Yusim K., Foley B., Gao F., Lang D., et al. Diversity considerations in HIV-1 vaccine selection. Science 2002, 296(5577):2354-2360.
16. Nickle D.C., Jensen M.A., Gottlieb G.S., Shriner D., Learn G.H., Rodrigo A.G., et al. Consensus and ancestral state HIV vaccines. Science 2003, 299(March (5612)):1515-1517.
17. Gao F., Korber B.T., Weaver E., Liao H.X., Hahn B.H., Haynes B.F. Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity. Expert Rev Vaccines 2004, 3(August (Suppl. 4)):S161-S168.
18. Kesturu G.S., Colleton B.A., Liu Y., Heath L., Shaikh O.S., Rinaldo C.R., et al. Minimization of genetic distances by the consensus, ancestral, and center-of-tree (COT) sequences for HIV-1 variants within an infected individual and the design of reagents to test immune reactivity. Virology 2006, 348(May (2)):437-448.
19. Frahm N., Korber B.T., Adams C.M., Szinger J.J., Draenert R., Addo M.M., et al. Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol 2004, 78(March (5)):2187-2200.
20. Gao F., Weaver E.A., Lu Z., Li Y., Liao H.X., Ma B., et al. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus Type 1 group M consensus envelope glycoprotein. J Virol 2005, 79(2):1154-1163.
21. Santra S., Korber B.T., Muldoon M., Barouch D.H., Nabel G.J., Gao F., et al. A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. Proc Natl Acad Sci USA 2008, 105(30):10489-10494.
22. Serwanga J., Mugaba S., Pimego E., Nanteza B., Lyagoba F., Nakubulwa S., et al. Profile of T cell recognition of HIV Type 1 consensus group M Gag and Nef peptides in a clade A1- and D-infected Ugandan population. AIDS Res Hum Retroviruses 2012, 28(4):384-392.
23. Kothe D.L., Li Y.Y., Decker J.M., Bibollet-Ruche F., Zammit K.P., Salazar M.G., et al. Ancestral and consensus envelope immunogens for HIV-1 subtype C. Virology 2006, 352(September (2)):438-449.
24. Santra S., Korber B.T., Muldoon M., Barouch D.H., Nabel G.J., Gao F., et al. A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. Proc Natl Acad Sci USA 2008, 105(July (30)):10489-10494.
25. Yan J., Corbitt N., Pankhong P., Shin T., Khan A., Sardesai N.Y., et al. Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine. Vaccine 2011, 29(September (41)):7173-7181.
26. Frahm N., Nickle D.C., Linde C.H., Roach T., Walker B.D., Allen T.M., et al. Increased detection of HIV-specific T cell responses by combination of central sequences with comparable immunogenicity. AIDS 2008, 22(February (4)):447-456.
27. Bansal A., Gough E., Ritter D., Wilson C., Mulenga J., Allen S., et al. Group M-based HIV-1 Gag peptides are frequently targeted by T cells in chronically infected US and Zambian patients. AIDS 2006, 20(February (3)):353-360.
28. Zembe L., Burgers W.A., Jaspan H.B., Bekker L.G., Bredell H., Stevens G., et al. Intra- and inter-clade cross-reactivity by HIV-1 Gag specific T-cells reveals exclusive and commonly targeted regions: implications for current vaccine trials. PLoS One 2011, 6(10):e26096.
29. Williams F., Meenagh A., Darke C., Acosta A., Daar A.S., Gorodezky C., et al. Analysis of the distribution of HLA-B alleles in populations from five continents. Hum Immunol 2001, 62(June (6)):645-650.
30. Sierra M., Thomson M., Ríos M., Casado G., Castro R., Delgado E., et al. The analysis of near full-length genome sequences of human immunodeficiency virus type 1 BF intersubtype recombinant viruses from Chile, Venezuela and Spain reveals their relationship to diverse lineages of recombinant viruses related to CRF12_BF. Infect Genet Evol 2005, 5(April (3)):209-217.
31. Heyndrickx L., Janssens W., Zekeng L., Musonda R., Anagonou S., Van Der Auwera G., et al. Simplified strategy for detection of recombinant human immunodeficiency virus type 1 group M isolates by gag/env heteroduplex mobility assay. Study group on heterogeneity of HIV epidemics in African cities. J Virol 2000, 74(January (1)):363-370.
32. Lee C.N., Chen M.Y., Lin H.S., Lee M.C., Luo C.C., Twu S.J., et al. HIV type 1 env subtype A variants in Taiwan. AIDS Res Hum Retroviruses 1998, 14(June (9)):807-809.
33. Artenstein A., Hegerich P., Beyrer C., Rungruengthanakit K., Michael N., Natpratan C. Sequences and phylogenetic analysis of the nef gene from Thai subjects harboring subtype E HIV-1. AIDS Res Hum Retroviruses 1996, 12(April (6)):557-560.
34. Salvi R., Garbuglia A.R., Di Caro A., Pulciani S., Montella F., Benedetto A. Grossly defective Nef gene sequences in a human immunodeficiency virus type 1-seropositive long-term nonprogressor. J Virol 1998, 72(May (5)):3646-3657.
35. Tamura K., Dudley J., Nei M., Kumar S. MEGA4. Molecular evolutionary genetics analysis (MEGA) software version 4. 0. Mol Biol Evol 2007, 24(August (8)):1596-1599.
36. Cunha-Neto E., Felgueiras C., Manuel M., Samri A., Coutinho R., Côrtes F., et al. T cell crossreactivity of Gag and Nef epitopes derived from Brazilian and European HIV-1 strains among Brazilian and French HIV-1-infected patients. Aids Res Hum Retroviruses 2008, 24(Suppl. 1). S124-S124.
37. Calarota S.A., Foli A., Maserati R., Baldanti F., Paolucci S., Young M.A., et al. HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals. J Immunol 2008, 180(9):5907-5915.
38. Coplan P.M., Gupta S.B., Dubey S.A., Pitisuttithum P., Nikas A., Mbewe B., et al. Cross-reactivity of anti-HIV-1T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents. J Infect Dis 2005, 191(May (9)):1427-1434.
39. Gupta S.B., Mast C.T., Wolfe N.D., Novitsky V., Dubey S.A., Kallas E.G., et al. Cross-clade reactivity of HIV-1-specific T-cell responses in HIV-1-infected individuals from Botswana and Cameroon. J Acquir Immune Defic Syndr 2006, 42(June (2)):135-139.
40. Geels M.J., Dubey S.A., Anderson K., Baan E., Bakker M., Pollakis G., et al. Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus Type 1 non-B clades (A-G): importance of HLA anchor residue conservation. J Virol 2005, 79(September (17)):11247-11258.
41. Betts M.R., Krowka J., Santamaria C., Balsamo K., Gao F., Mulundu G., et al. Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians. J Virol 1997, 71(November (11)):8908-8911.
42. Thakar M.R., Bhonge L.S., Lakhashe S.K., Shankarkumar U., Sane S.S., Kulkarni S.S., et al. Cytolytic T lymphocytes (CTLs) from HIV-1 subtype C-infected Indian patients recognize CTL epitopes from a conserved immunodominant region of HIV-1 Gag and Nef. J Infect Dis 2005, 192(September (5)):749-759.
43. Yu X.G., Lichterfeld M., Perkins B., Kalife E., Mui S., Chen J., et al. High degree of inter-clade cross-reactivity of HIV-1-specific T cell responses at the single peptide level. AIDS 2005, 19(September (14)):1449-1456.
44. McKinnon L.R., Ball T.B., Kimani J., Wachihi C., Matu L., Luo M., et al. Cross-clade CD8(+) T-cell responses with a preference for the predominant circulating clade. J Acquir Immune Defic Syndr 2005, 40(November (3)):245-249.
45. Turk G., Gherardi M.M., Laufer N., Saracco M., Luzzi R., Cox J.H., et al. Magnitude, breadth, and functional profile of T-cell responses during human immunodeficiency virus primary infection with B and BF viral variants. J Virol 2008, 82(6):2853-2866.
46. Bongertz V., Teixeira S., Grinztejn B., Pilotto J., Veloso V., Morgado M., et al. Human immunodeficiency virus type 1 neutralization by plasma from B or F genotype infected individuals. Mem Inst Oswaldo Cruz 2005, 100(February (1)):85-89.
47. Serwanga J., Mugaba S., Pimego E., Nanteza B., Lyagoba F., Nakubulwa S., et al. Profile of T Cell Recognition of HIV Type 1 consensus Group M Gag and Nef Peptides in a Clade A1- and D-Infected Ugandan Population. AIDS Res Hum Retroviruses 2012, 28(4):384-392.
48. Brown S.A., Slobod K.S., Surman S., Zirkel A., Zhan X., Hurwitz J.L. Individual HIV Type 1 envelope-specific T cell responses and epitopes do not segregate by virus subtype. AIDS Res Hum Retroviruses 2006, 22(February (2)):188-194.